Pharmacologic Treatment for Sleep Maintenance Insomnia After Failed CBT
For your 42-year-old patient with sleep maintenance insomnia who has failed CBT, start with either suvorexant (10-20 mg), low-dose doxepin (3-6 mg), eszopiclone (2-3 mg), or zolpidem (10 mg) as first-line pharmacologic options.
Primary Medication Options for Sleep Maintenance
The American Academy of Sleep Medicine 2017 guideline specifically identifies four medications with evidence for treating sleep maintenance insomnia 1:
First-Tier Choices:
Suvorexant (orexin receptor antagonist): 10,15/20, or 20 mg at bedtime
- Specifically recommended for sleep maintenance insomnia
- Newer mechanism targeting wakefulness pathways rather than sedation
- Lower abuse potential compared to benzodiazepines
Doxepin (low-dose tricyclic): 3-6 mg at bedtime
- Specifically targets sleep maintenance through histamine H1 antagonism
- Evidence-based at these low doses (not antidepressant doses)
- Minimal anticholinergic effects at low doses
Eszopiclone (non-benzodiazepine): 2-3 mg at bedtime
- Covers both sleep onset AND maintenance
- Longer half-life than other Z-drugs
Zolpidem (non-benzodiazepine): 10 mg at bedtime (5 mg for women per FDA)
- Also addresses both onset and maintenance
- Critical caveat: FDA mandates lower dosing in women (5 mg) due to impaired next-day driving 2
Second-Tier Option:
- Temazepam (benzodiazepine): 15 mg at bedtime 1
- Effective for maintenance insomnia but higher risk profile
- Concerns about dependence, tolerance, and cognitive effects
- Reserve for when first-tier options fail
What NOT to Use
The guidelines explicitly recommend AGAINST several commonly prescribed options 1:
- Trazodone (50 mg): Despite widespread off-label use, evidence shows harms outweigh benefits
- Diphenhydramine/antihistamines: Not recommended due to anticholinergic effects and limited efficacy
- Melatonin (standard formulation): Ineffective for maintenance insomnia
- Tiagabine: Harms outweigh benefits
Practical Implementation Strategy
Step 1: Choose based on patient factors
- If concerned about abuse potential or patient has substance use history → Suvorexant or low-dose doxepin
- If cost is a barrier (suvorexant expensive) → Eszopiclone or zolpidem
- If patient is female → Zolpidem 5 mg (not 10 mg) or choose alternative
- If patient is older (>65) → Low-dose doxepin 3 mg (safest profile in elderly)
Step 2: Set clear expectations
- Prescribe for short-term use initially (≤4 weeks) 1, 3
- Explain this is to break the insomnia cycle while reinforcing CBT principles
- Schedule follow-up in 2-4 weeks to reassess
Step 3: Monitor for specific risks
- All Z-drugs and benzodiazepines: Complex sleep behaviors (sleep-driving), next-day impairment, falls risk
- Suvorexant: Next-day somnolence, abnormal dreams
- Doxepin: Morning grogginess at higher doses, weight gain with chronic use
Important Caveats
The evidence quality is only moderate - all recommendations in the AASM guideline are "WEAK" recommendations with low to very low quality evidence 1. This reflects that:
- Most trials were short-term (≤4 weeks)
- Large placebo responses occur (30-48% improvement rates) 2
- Long-term efficacy and safety data are limited
Avoid chronic daily use without reassessment. While the guidelines suggest longer-term use "may be initiated in some cases" 4, the European guidelines emphasize that benzodiazepines and Z-drugs should be limited to ≤4 weeks, with orexin antagonists potentially used up to 3 months 4.
The 2023 European update confirms these recommendations but adds daridorexant (another orexin antagonist) as an option for up to 3 months or longer 4.
Clinical Bottom Line
Since CBT has failed, pharmacologic intervention is appropriate. Choose suvorexant or low-dose doxepin as safest long-term options, or eszopiclone/zolpidem for cost-effectiveness, avoiding trazodone despite its popularity. Prescribe initially for 4 weeks, then reassess whether continued use is justified versus attempting intermittent dosing or medication holidays.